NASDAQ · LFVN

Lifevantage Corporation (Delaware)

$6.37 -$0.16 (-2.45%) 1D Market open

Key Metrics

$82.38M
Market cap
14.32×
P/E · TTM
$195.32M
Revenue · TTM
$5.75M
Net income
EPS · TTM $0.45
Dividend yield 2.8%
Free cash flow $3.78M
Beta · 1Y 0.86
EBITDA · TTM $9.59M
Gross margin 78.1%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 16
    From its Jun 8 high, the share price fell 44%.

    Peak close $10.70 on Jun 8; trough close $6.04 on Jun 16. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -44%
  • Jun 15
    The stock moved -27.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 15
  • May 26
    The stock moved +23.5% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 26

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$82.38M
Enterprise value
Shares outstanding12.6M
52-wk range$3.90 – $15.00
Avg volume · 20D107.1K
Net cash
Book value / share$2.61
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Lifevantage Corporation (Delaware)
IPO dateMar 10, 1997
Employees238

Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E14.32
P/S0.42
P/FCF21.82
EV/EBITDA
EV/Sales
Graham №$5.15

Profitability

Gross 78.1%
Operating 3.5%
Net 2.9%
FCF 1.9%
ROE / ROIC 19.4% · —

Financial Health

Current ratio1.96
Quick ratio1.04
Debt / equity
Debt / EBITDA
Net cash
Working capital$19.21M

Cash Flow · TTM

Operating CF $6.51M
Capex −$2.73M
Free cash flow $3.78M
Buybacks $4.73M
Dividends paid $2.28M
Shareholder yield 8.5%

Piotroski F-Score

6 / 9
Middling fundamentals · 6 of 9 signals passing

Altman Z-Score

3.3
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

$5.15 vs $6.37
Trades 1.2× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings